EOFlow faces delisting after Corporate Review Committee decision

The Corporate Review Committee decided to delist EOFlow.

The committee made the decision on the 19th.

First-half revenue fell to 222 million won ($157,335) from 1.9 billion won ($1.34 million) a year earlier. EOFlow linked the decline to its dispute with Insulet, saying concerns over business continuity and product supplies delayed new prescriptions and contracts, while existing users left or switched to rival products.

On May 28, the U.S. Court of Appeals for the Federal Circuit overturned a lower-court ruling in litigation brought by Insulet alleging trade-secret misappropriation and patent infringement by EOFlow.

EOFlow said in a statement, "Going forward, we will continue to contribute to improving the quality of life for people living with diabetes through more stable product supplies, improved service quality and innovation in digital healthcare technology."

On June 23, restrictions on recruiting new domestic users and selling its EOPatch disposable insulin patch pump were temporarily lifted under a U.S. federal appeals court order.